ResMed Inc. (NYSE:RMD) Shares Sold by Triodos Investment Management BV

Share on StockTwits

Triodos Investment Management BV cut its stake in ResMed Inc. (NYSE:RMD) by 25.0% in the third quarter, HoldingsChannel reports. The fund owned 15,000 shares of the medical equipment provider’s stock after selling 5,000 shares during the period. Triodos Investment Management BV’s holdings in ResMed were worth $2,027,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in ResMed by 1.4% in the second quarter. Vanguard Group Inc. now owns 15,327,232 shares of the medical equipment provider’s stock valued at $1,870,382,000 after acquiring an additional 212,459 shares during the period. WCM Investment Management LLC lifted its holdings in ResMed by 6.2% in the third quarter. WCM Investment Management LLC now owns 7,666,764 shares of the medical equipment provider’s stock valued at $1,035,857,000 after acquiring an additional 450,954 shares during the period. Baillie Gifford & Co. lifted its holdings in ResMed by 0.6% in the second quarter. Baillie Gifford & Co. now owns 4,824,334 shares of the medical equipment provider’s stock valued at $588,714,000 after acquiring an additional 26,553 shares during the period. Northern Trust Corp lifted its holdings in ResMed by 1.9% in the second quarter. Northern Trust Corp now owns 1,992,027 shares of the medical equipment provider’s stock valued at $243,087,000 after acquiring an additional 37,217 shares during the period. Finally, Invesco Ltd. lifted its holdings in ResMed by 208.2% in the second quarter. Invesco Ltd. now owns 1,955,124 shares of the medical equipment provider’s stock valued at $238,584,000 after acquiring an additional 1,320,770 shares during the period. 66.45% of the stock is owned by institutional investors.

In other news, CEO Michael J. Farrell sold 6,651 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $132.35, for a total value of $880,259.85. Following the transaction, the chief executive officer now owns 292,988 shares of the company’s stock, valued at approximately $38,776,961.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Brett Sandercock sold 3,000 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $139.21, for a total value of $417,630.00. Following the completion of the transaction, the chief financial officer now directly owns 76,145 shares in the company, valued at approximately $10,600,145.45. The disclosure for this sale can be found here. Insiders have sold 60,112 shares of company stock valued at $8,139,860 over the last quarter. 1.22% of the stock is owned by company insiders.

A number of analysts have recently commented on the company. ValuEngine cut ResMed from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research report on Friday, October 25th. UBS Group upgraded ResMed from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $122.00 to $140.00 in a research report on Monday, July 29th. Finally, Goldman Sachs Group upgraded ResMed from a “neutral” rating to a “buy” rating in a research report on Monday, July 29th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $121.50.

Shares of RMD traded up $1.67 during trading hours on Friday, hitting $143.85. 371,556 shares of the stock were exchanged, compared to its average volume of 738,537. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.46 and a current ratio of 2.11. ResMed Inc. has a 12-month low of $90.64 and a 12-month high of $149.96. The company has a market cap of $20.76 billion, a price-to-earnings ratio of 39.52, a price-to-earnings-growth ratio of 2.76 and a beta of 0.41. The stock’s 50-day moving average price is $135.96 and its two-hundred day moving average price is $125.98.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.06. ResMed had a return on equity of 26.72% and a net margin of 15.52%. The firm had revenue of $681.06 million during the quarter, compared to analysts’ expectations of $660.87 million. During the same period in the previous year, the business earned $0.81 earnings per share. The firm’s revenue for the quarter was up 15.8% on a year-over-year basis. On average, research analysts expect that ResMed Inc. will post 4.04 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 1.08%. The ex-dividend date is Wednesday, November 6th. ResMed’s payout ratio is 42.86%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Article: Should You Consider an Index Fund?

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Whitnell & Co. Buys 824 Shares of First Trust Managed Municipal ETF
Whitnell & Co. Buys 824 Shares of First Trust Managed Municipal ETF
Whitnell & Co. Has $3.28 Million Stock Position in iShares Russell 2000 ETF
Whitnell & Co. Has $3.28 Million Stock Position in iShares Russell 2000 ETF
ResMed Inc.  Shares Sold by Triodos Investment Management BV
ResMed Inc. Shares Sold by Triodos Investment Management BV
Whitnell & Co. Has $4.63 Million Stock Position in Intel Co.
Whitnell & Co. Has $4.63 Million Stock Position in Intel Co.
Gamble Jones Investment Counsel Has $1.32 Million Holdings in iShares Floating Rate Bond ETF
Gamble Jones Investment Counsel Has $1.32 Million Holdings in iShares Floating Rate Bond ETF
Teekay Tankers Ltd.  Shares Bought by Monarch Partners Asset Management LLC
Teekay Tankers Ltd. Shares Bought by Monarch Partners Asset Management LLC


© 2006-2019 Ticker Report